EOLS News and Press, Evolus Inc. From 08/30/22

Evolus ( NASDAQ: EOLS ) on Tuesday has named Sandra Beaver as its chief financial officer, effective Sept. 5, 2022. Most recently, Beaver served as Senior Vice President of Finance at Experian ( OTCQX:EXPGF ) and previously has worked for 17 years with&#...

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, has named Sandra Beaver as its Chief Financial Officer, effective September 5, 2022. Ms. Beaver brings more than 20 years of financial experience, driv...

Summary Form 483 observation in press release did not contain important detail. Burkholderia cepacia complex contamination found in manufacturing process. Inspection may not be closed out two weeks before PDUFA. Bacterial Contamination Even though Revance Therapeutic...

Results demonstrated percentages of male responders treated with Jeuveau ® achieved approximately 10% higher results across all visits Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough p...

Evolus, Inc. (EOLS) Q2 2022 Earnings Conference Call August 01, 2022, 9:00 AM ET Company Participants David Erickson - Vice President, Investor Relations David Moatazedi - President and Chief Executive Officer Rui Avelar - Chief Medical Officer and Head of Resear...

Evolus ( NASDAQ: EOLS ) is trading down ~13% after the company posted mixed results for the second quarter and full-year guidance that missed estimates. The company reaffirmed 2022 net revenue guidance of upper end of $143M to $150M vs. consensus of $150.27M. ...

Gainers: Quoin Pharmaceuticals ( QNRX ) +45% . Context Therapeutics CNTX +13% . Rhythm Pharmaceuticals RYTM +13% . Harmony Biosciences HRMY +10% . Nautilus Biotechnology NAUT +9% . Losers: Ontrak OTRK -43% . Phathom Pharmaceutical...

Evolus press release ( NASDAQ: EOLS ): Q2 GAAP EPS of -$0.42 misses by $0.11 . Revenue of $37.2M (+42.5% Y/Y) beats by $0.55M . Gross profit margin and adjusted gross profit margin were 55.4% and 57.4%, respectively. Reaffirms Full-Year 2022 net revenue gui...

Q2 2022 Net Revenue of $37.2 Million, Up 42% from Q2 2021 Reaffirms Full-Year 2022 Net Revenue Guidance of Upper End of $143 to $150 Million European Launch to Commence in Q3 2022 Strong Cash Position of $84.5 Million Expected to Fund Company to Breakeven ...

Evolus ( NASDAQ: EOLS ) is scheduled to announce Q2 earnings results on Tuesday, August 2nd, before market open. The consensus EPS Estimate is -$0.24 (+22.6% Y/Y) and the consensus Revenue Estimate is $36.65M (+40.4% Y/Y). Over the last 3 months, EPS estimates have see...